Entero Healthcare Solutions Limited has announced an earnings call scheduled for February 07, 2026, to discuss its unaudited financial results for the quarter and nine months ended December 31, 2025. The company informed the BSE and NSE about this development through a regulatory filing dated February 06, 2026, in compliance with Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements.

Management Participation

The earnings call will feature senior management representatives who will engage with analysts and investors to discuss the company's Q3FY26 performance. The management team participating in the call includes key leadership positions across different operational areas.

Call Details and Access

DAM Capital Advisors Ltd will host the post-results conference call, with Nitin Agarwal serving as the lead analyst. The call will be accessible through multiple dial-in options to accommodate participants from various networks and countries.

International Participation

The earnings call has been scheduled to accommodate international participants across different time zones. The company has provided specific timing details for major international markets to ensure global investor participation.

Regulatory Compliance

The announcement was made through proper regulatory channels, with Company Secretary and Compliance Officer Sanu Kapoor signing the notification. The company emphasized that discussions during the call will be based on publicly available information, maintaining transparency standards. The filing also noted that changes may occur due to exigencies on the part of the host or company.

Entero Healthcare Solutions has informed stock exchanges about a temporary suspension of its subsidiary's drug manufacturing license, marking a regulatory setback for the pharmaceutical company. The disclosure was made on January 27, 2026, in compliance with SEBI listing regulations.

Regulatory Action Details

The Senior Drugs Control Officer cum Licensing Authority, Karnal Zone, has temporarily suspended the drug license of Atreja Healthcare Solutions Private Limited, a wholly owned subsidiary of Entero Healthcare Solutions. The suspension is effective for three days, from January 30, 2026, to February 1, 2026.

Violation Specifics

The temporary suspension was imposed as an administrative action for contraventions of provisions under the Drugs and Cosmetics Act, 1940, read with rule 64 and 65 (5) of the Drugs and Cosmetics Rules, 1945. The regulatory action was taken while Atreja was conducting its business operations.

Financial Impact Assessment

The company has provided a detailed assessment of the suspension's impact on its operations and financial performance:

Regulatory Compliance

Entero Healthcare Solutions filed this disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The disclosure was signed by Sanu Kapoor, Vice President-General Counsel, Company Secretary & Compliance Officer, ensuring proper corporate governance protocols were followed in communicating this development to stakeholders and regulatory authorities.